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Pulmonary hypertension (PH) is a uniformly progressive, fatal disease 
characterized by right-ventricle failure and defined by levels of mean pulmonary arterial 
pressure (mPAP) ≥25mmHg [1]. The term pulmonary arterial hypertension (PAH) 
implies a patient subset with pre-capillary PH, being levels of pulmonary artery wedge 
pressure (PAWP) ≤15mmHg and pulmonary vascular resistance (PVR) >3U/m [1]. A 
greater understanding of the disease has led to important therapeutic advances [2]. Yet 
the mean survival rates of PAH patients at 1, 3, 5 and 7yrs has been recently estimated 
at 91%, 74%, 65% and 59%, respectively [3]. Identification of valid predictors of 
survival is thus of paramount importance to help monitoring these patients and guiding 
their treatment.  
Non-invasive survival predictors derived from cardiopulmonary exercise testing 
(CPET) and 6-min walk distance (6MWD) have gained attention in recent years. 
However, there is yet no consensus on which variable or variable combination is more 
informative. Here we determined the 2yr and 4yr predictive value of CEPT-related 
variables and 6MWD in a relatively large cohort of PAH Spanish patients, representing 
~27% of the national registry. 
  Informed consent was obtained from each patient and the study protocol 
conformed to the ethical guidelines of the 1975 Declaration of Helsinki as reflected in a 
priori approval by the institution's human research committee. We performed a cohort-
retrospective analysis of PAH patients referred to the ‘12 de Octubre’ Hospital (Madrid, 
Spain), which is where all assessments took place (June 2006-June 2013) and meeting 
the following criteria: mPAP≥25mmHg, PAWP≤15mmHg, PVR>3U/m, aged >18yrs 
and having performed CPET followed by 6MWD within 1wk. CPET was performed 
using an electromagnetically-braked cycle-ergometer adhering to the American 
Thoracic Society guidelines (ATS/ACCP Statement on Cardiopulmonary exercise 
testing, 2003) and gas-exchange variables were collected breath-by-breath and averaged 
over 10sec. 6MWD was measured according to a standardized protocol following ATS 
guidelines [4].  
We compared 6MWD, CPET-variables and N-terminal pro-B-type natriuretic 
peptide (NT-proBNP) blood levels among survivors and non-survivors at 2 and 4yr 
follow-up from baseline (i.e., from time of CPET), with an unpaired t-test. For those 
variables showing statistical significance at 2 or 4yrs, we calculated the Receiver-
Operator Curve (ROC). The optimal cut-off point for predicting survival was 
determined by the Youden Index. Areas under the curve (AUC), 95% confidence 
interval (95%CI), specificity and sensitivity were calculated. Values of AUC=1, ≥0.90, 
=0.80-0.90, =0.70-0.79 and <0.70 are indicative of perfect, excellent, good, fair and 
poor prediction, respectively. Cox proportional hazard analyses were also performed. 
Kaplan-Meier survival analyses from CPET (right-censored) and from time of diagnosis 
(left-truncated and right-censored) were calculated for those variables with an 
AUC>0.5. 
We followed 148 patients (30%male) during a mean of 2380(range: 2242-2519) 
days with the main etiologies being idiopathic (67%), and connective tissue (17%) or 
congenital heart disease (10%). Their  baseline characteristics were: age (mean±SD) age 
49±13yrs (18-83), WHO-categories I(23%), II(55%), III(21%) and IV(1%), NT-
proBNP (mean interquartile range)=602(66-792)pg/ml, 6MWD=474±100meters, and 
peak oxygen uptake (VO2peak)=17±6ml/kg/min. Treatment strategies were 
standardized with main medications at baseline being diuretics (57% of patients), 
anticoagulants (81%), digoxin (11%), oxygen supplementation (25%) prostacyclin 
analogues (39%),  bosentan/sitaxsetan (45%) and sildenafil (59%).  
 
Thirteen patients died [heart failure (n=8), infection (n=1), sudden death (n=1), 
cerebral vascular accident (n=1), or unknown reason (n=2)] and 6 were scheduled for 
lung transplantation over the 4yr follow-up. The best predictor was the NT-proBNP, 
which showed good and fair ability for predicting non-survival at 2 (≥917pg/mL) and 
4yrs (≥914pg/mL), respectively (Table 1). None of the equations defined by further 
logistic regression analysis for combinations of the different exercise-related variables 
proved better predictors of 2 or 4yr survival (all AUC<0.75) than these variables 
individually (data not shown for simplicity purposes). 
Univariate Cox proportional hazard analyses revealed the following significant 
hazard ratio (HR) values at 2yrs: HR=0.67(95%CI:0.46-0.97;p=0.036) for every 12-watt 
increase in peak watts during CPET; HR=1.07(95%CI:1.00-1.10;p=0.020) for the 
ventilatory equivalent of carbon dioxide at the anaerobic threshold (VE/VCO2@AT); 
HR=0.84(95%CI:0.73-0.94;p=0.008) for every 30-meter increase in 6MWD; and 
HR=1.25(95%CI:1.10-1.42;p<0.001) for every 300pg/mL increase in NT-proBNP. At 
4yrs, a significant HR was found for the abovementioned quantitative changes in peak 
watts [HR=0.72(95%CI:0.52-1.00;p=0.050)], 6MWD [HR=0.84(95%CI:0.743-
0.942);p=0.003] and NT-proBNP [HR=1.215(95%CI:1.07-1.37);p=0.001], as well as 
for VE/VCO2@AT [HR=1.063(95%CI:1.01-1.12);p=0.014] and end-tidal pressure of 
carbon dioxide at the anaerobic threshold (PETCO2@AT) [HR=0.95(95%CI:0.91-0.99); 
p=0.025). In multivariate Cox analyses, 300pg/mL-increases in NT-proBNP yielded a 
significant HR value, at both 2yrs [HR=1.20(95%CI:1.01-1.42);p=0.026] and 4yrs 
[HR=1.30(95%CI:1.04-1.63);p=0.017]. Backward and forward stepwise analyses 
yielded the same results. 
Kaplan-Meier survival analyses showed that patients with both NT-
proBNP<914pg/ml and PETCO2@AT≥30mmHg [87%(65-91)] had a significantly better 
prognosis over the 4yr follow-up (p<0.05) than those with other value combinations 
(Figure 1, left panel). No events were, in fact, registered for those patients (n=47) with 
NT-proBNP and PETCO2@AT values below and above such cut-offs, respectively. 
Patients with both NT-proBNP<914pg/ml and VE/VCO2@AT<39 [98%(87-99)] had a 
significantly better prognosis over the 4yr follow-up (p<0.05) than those with other 
value combinations (Figure 1, right panel). 
It is urgent to determine useful indicators of mid/long-term survival in large 
PAH patient cohorts. In this regard, our study is the first of this type in a Spanish cohort 
and had a comparatively large sample size and a long follow-up with regards to most 
previous investigations in the field [5-8]. The main insights obtained from our results 
are three-fold: (1) the NT-proBNP proved better predictor of 2 or 4yr survival than 
exercise-related variables, although the PETO2@AT can also provide useful information 
regarding 4yr-survival (combining good specificity/sensitivity with a fair predictive 
potential); (2) the combination of NT-proBNP<914pg/ml and PETCO2@AT≥30mmHg 
had prognostic value over the 4yr-period; and (3) there does not seem to be a potential 
algorithm combining 6MWD/CPET variables showing a better predictive capacity 
compared with individual variables separately, and certainly not compared with NT-
proBNP. On the other hand, despite the simplicity and widespread use of the 6WMD, its 
cut-off value to differentiate survivors vs. non-survivors was not sensitive along time in 
our cohort, showing a similar value to predict 2 and 4yr survival. A certain ‘ceiling 
effect’ in 6MWD may mask treatment efficacy [9,10] and there is yet not a clear 
consensus about the use of a  predictive threshold value.  
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 Figure 1 legend. 4yr Kaplan-Meier survival curves. Abbreviations: NT-proBNP, N-
terminal pro-B-type natriuretic peptide; PETCO2@AT, end-tidal pressure of carbon 
dioxide at anaerobic threshold; VE/VCO2@AT, ventilatory equivalent for carbon 
dioxide at anaerobic threshold. 
 

                                         Table 1. Receiver operating characteristic (ROC) results over the study period.  
 
  Follow-up Cut-off  AUC  95%CI P-value Standard Error 
Sensitivity 
(%) 
Specificity 
(%) 
 VO2peak 
(ml/kg/min) 
2yrs ≥15 0.64 (0.53,0.76) 0.07 0.06 61 73 
Su
rv
iv
al
 
4yrs ≥15 0.70 (0.59,0.80) 0.01 0.05 67 74 
 
6MWD 
(meters) 
 
2yrs ≥463 0.71 (0.59,0.82) 0.01 0.06 57 87 
4yrs ≥464 0.73 (0.62,0.83) <0.01 0.05 56 90 
Peak watts 
 
2yrs ≥63 0.68 (0.57,0.80) 0.03 0.06 41 93 
 4yrs ≥68 0.66 (0.54,0.76) 0.04 0.06 30 100 
 
PETCO2@AT 
(mmHg) 4yrs ≥30 0.72 (0.58,0.85) <0.01 0.07 62 81  
N
on
-s
ur
vi
va
l 
 
NT-proBNP 
(pg/ml) 
 
2yrs ≥917 0.82 (0.73,0.92) <0.01 0.05 77 80 
4yrs ≥914 0.79 (0.69,0.89) <0.01 0.05 75 77 
         
VE/VCO2@AT 
2yrs ≥39 0.70 (0.55,0.86) 0.01 0.08 71 76 
4yrs ≥39 0.71 (0.57,0.85) 0.01 0.07 63 78 
          
 
Abbreviations: 6MWD, six minute walk distance; 95%CI, 95% confidence interval; AT, anaerobic threshold; AUC, area under the curve; NT-ProBNP, N-terminal pro-B-type 
natriuretic peptide; PETCO2@AT, end-tidal pressure of carbon dioxide at anaerobic threshold; VE/VCO2@AT, ventilatory equivalent for carbon dioxide at anaerobic threshold; 
VO2peak, peak oxygen uptake. Significant p-values are in bold.  
